NewAmsterdam Pharma Company N.V. (NAMSW) has a negative trailing P/E of -19.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 14.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -5.19%, forward earnings yield 6.79%. PEG 0.11 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 53/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2020 | -26.8 | 0.00 | 1.48 | 0.00 | - |
| 2021 | -4.1 | -0.02 | 3.06 | 0.00 | - |
| 2022 | -9.1 | 0.14 | 0.48 | 2.01 | - |
| 2023 | -5.2 | -0.06 | 3.18 | 65.13 | - |
| 2024 | -10.0 | -0.53 | 3.20 | 53.22 | - |
| 2025 | -19.7 | 0.62 | 5.87 | 178.34 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2020 | $-1.15 | $0.00 | $-5.75M | - |
| 2021 | $-3.34 | $0.00 | $-36.71M | - |
| 2022 | $-1.11 | $95.91M | $-21.14M | -22% |
| 2023 | $-2.15 | $12.76M | $-176.94M | -1386.4% |
| 2024 | $-2.56 | $45.56M | $-241.6M | -530.3% |
| 2025 | $-1.75 | $22.5M | $-203.82M | -905.7% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.91 | $-8.79 – $0.20 | $25.62M | $3.85M – $96.44M | 1 |
| 2027 | $-1.39 | $-6.37 – $0.15 | $159.59M | $23.97M – $600.67M | 1 |
| 2028 | $-0.21 | $-0.99 – $0.02 | $381.69M | $57.34M – $1.44B | 1 |
| 2029 | $1.59 | $-0.17 – $7.30 | $720.31M | $108.21M – $2.71B | 1 |
| 2030 | $3.66 | $-0.38 – $16.83 | $1.08B | $162.81M – $4.08B | 1 |
